Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | MGAM | O43451 | 2/20 | 0.56 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | SI | P14410 | 2/20 | 0.56 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.56 |
| ▸ | SLC9A1 | P19634 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP4Z1 | Q86W10 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535029 | 1.00 | ASAH1 (0.66) | ASAH1KMT2AHPGDHSD17B10MAPT | |
| SCHEMBL5793440 | 1.00 | ASAH1 (0.66) | ASAH1KMT2AHPGDHSD17B10MAPT | |
| SCHEMBL534899 | 1.00 | ASAH1 (0.66) | ASAH1KMT2AHPGDHSD17B10MAPT | |
| SCHEMBL535094 | 1.00 | ASAH1 (0.66) | ASAH1KMT2AHPGDHSD17B10MAPT | |
| SCHEMBL18206302 | 1.00 | ASAH1 (0.66) | ASAH1KMT2AHPGDHSD17B10MAPT | |
| SCHEMBL534984 | 1.00 | ASAH1 (0.66) | ASAH1KMT2AHPGDHSD17B10MAPT | |
| SCHEMBL535030 | 0.99 | ASAH1 (0.64) | ASAH1KMT2AHPGDHSD17B10MAPT | |
| SCHEMBL23780256 | 0.94 | KMT2A (0.62) | ASAH1KMT2AHPGDHSD17B10MAPT | |
| SCHEMBL18932961 | 0.92 | ASAH1 (0.58) | ASAH1KMT2AHPGDHSD17B10MAPT | |
| SCHEMBL534954 | 0.92 | ASAH1 (0.58) | ASAH1KMT2AHPGDHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1956000-B1 | ACYLATING AGENTS USEFUL FOR ACYLATING PEPTIDES | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | disclosed |
| US-8097698-B2 | Derivatives of GLP-1 analogs | NOVO NORDISK A/S (DK) | 2012-01-17 | — | — | US | disclosed |
| EP-1060191-B1 | DERIVATIVES OF GLP-1 ANALOGS | NOVO NORDISK AS (DK) | 2010-04-28 | — | — | EP | disclosed |
| US-20090176700-A1 | Derivatives Of GLP-1 Analogs | NOVO NORDISK A/S (DK) | 2009-07-09 | — | — | US | disclosed |
| EP-1163211-B1 | METHOD FOR ACYLATING PEPTIDES AND PROTEINS | NOVO NORDISK AS (DK) | 2008-09-24 | — | — | EP | disclosed |
| EP-1956000-A1 | Acylating agents useful for acylating peptides | Novo Nordisk A/S (DK) | 2008-08-13 | — | — | EP | disclosed |
| US-7235627-B2 | Derivatives of GLP-1 analogs | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| US-20060199763-A1 | Derivatives of GLP-1 analogs | KNUDSEN LISELOTTE B | 2006-09-07 | — | — | US | disclosed |
| EP-0938502-B1 | SELECTIVE ACYLATION METHOD | NOVO NORDISK AS (DK) | 2004-10-06 | — | — | EP | disclosed |
| EP-1061946-B1 | GLP-1 DERIVATIVES WITH HELIX-CONTENT EXCEEDING 25 %, FORMING PARTIALLY STRUCTURED MICELLAR-LIKE AGGREGATES | NOVO NORDISK AS (DK) | 2004-04-28 | — | — | EP | disclosed |
| US-20010011071-A1 | DERIVATIVES OF GLP-1 ANALOGS | KNUDSEN LISELOTTE BJERRE (DK) | 2001-08-02 | — | — | US | disclosed |
| US-6268343-B1 | HUMAN GLUCAGON-LIKE PEPTIDE-1; MORE PROTRACTED PROFILE OF ACTION THAN THE PARENT PEPTIDES; TREATING DIABETES AND OBESITY; Liraglutide | NOVO NORDISK A/S (DK) | 2001-07-31 | — | — | US | disclosed |
| EP-1061946-A1 | GLP-1 DERIVATIVES WITH HELIX-CONTENT EXCEEDING 25 %, FORMING PARTIALLY STRUCTURED MICELLAR-LIKE AGGREGATES | NOVO NORDISK A/S (DK) | 2000-12-27 | — | — | EP | disclosed |
| EP-1060191-A1 | DERIVATIVES OF GLP-1 ANALOGS | NOVO NORDISK A/S (DK) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000055119-A1 | METHOD FOR ACYLATING PEPTIDES AND NOVEL ACYLATING AGENTS | NOVO NORDISK A/S (DK) | 2000-09-21 | — | — | WO | disclosed |
| WO-1999043706-A1 | DERIVATIVES OF GLP-1 ANALOGS | NOVO NORDISK A/S (DK) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999043341-A1 | GLP-1 DERIVATIVES WITH HELIX-CONTENT EXCEEDING 25 %, FORMING PARTIALLY STRUCTURED MICELLAR-LIKE AGGREGATES | NOVO NORDISK A/S (DK) | 1999-09-02 | — | — | WO | disclosed |
| EP-0938502-A1 | SELECTIVE ACYLATION METHOD | NOVO NORDISK A/S (DK) | 1999-09-01 | — | — | EP | disclosed |
| US-5905140-A | ACYLATING INSULIN, INSULIN ANALOGS, AND INSULIN PRECURSORS ON FREE EPSILON-AMINO GROUP OF LYSINE USING ACTIVATED AMIDE WITH ACYL GROUP IN POLAR SOLVENT IN PRESENCE OF BASE | NOVO NORDISK A/S, NOVO ALLE (DK) | 1999-05-18 | — | — | US | disclosed |
| WO-1998002460-A1 | SELECTIVE ACYLATION METHOD | NOVO NORDISK A/S (DK) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199763-A1 | Derivatives of GLP-1 analogs | GLP1R, GIPR, IAPP | ASAH1 1850/4885KMT2A 4314/4885HPGD 3166/4885 |
| US-20090176700-A1 | Derivatives Of GLP-1 Analogs | GLP1R, GIPR, IAPP | ASAH1 1850/4885KMT2A 4314/4885HPGD 3166/4885 |
| US-20010011071-A1 | DERIVATIVES OF GLP-1 ANALOGS | GLP1R, GIPR, IAPP | ASAH1 1850/4885KMT2A 4314/4885HPGD 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.